The world’s first commercially cloned dog, a 10-week old Labrador named Lancey, was delivered to Florida residents Edgar and Nina Otto this week by BioArts International, a Mill Valley, Cailf.-based biotech startup.
The Ottos were one of five families to bid and win an auction held by BioArts International in July for a chance to clone their family dog. Lancey’s genetic donor, Sir Lancelot, died in January, 2008, and the Ottos had his DNA stored. By October, samples from the original dog were on their way to the Sooam Biotech Research Foundation in Seoul, South Korea, which provides cloning services to BioArts.
Lancey was born on November 18th, 2008, and brought to the US on January 25th, 2009 after being weaned from his surrogate mother.
BioArts International is a biotech company focused on untapped markets in the global companion animal, stem cell, and human genomics industries. The Best Friends Again program is a collaboration between BioArts and the Sooam Biotech Research Foundation in South Korea.
BioArts has been granted the sole, worldwide license for the cloning of dogs, cats and endangered species. The license was granted by Start Licensing, Inc. and applies to the somatic cell nuclear transfer (SCNT) cloning patents developed at the Roslin Institute for the cloning of Dolly the sheep.
Release Date: January 26, 2009
Source: BioArts International
Filed Under: Genomics/Proteomics
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)
